

Product datasheet for **TL314477V**

BID Human shRNA Lentiviral Particle (Locus ID 637)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	BID Human shRNA Lentiviral Particle (Locus ID 637)
Locus ID:	637
Synonyms:	FP497
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	BID - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001196 , NM_001244567 , NM_001244569 , NM_001244570 , NM_001244572 , NM_197966 , NM_197967 , NM_001196.1 , NM_001196.2 , NM_001196.3 , NM_197966.1 , NM_197966.2 , NM_197967.1 , NM_197967.2 , NM_001244569.1 , NM_001244570.1 , NM_001244572.1 , NM_001244567.1 , BC036364 , BC036364.1 , BC005884 , BC009197 , BC022072 , BC033634 , BM561391 , BM842561
UniProt ID:	P55957
Summary:	This gene encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2, and thus regulate apoptosis. The encoded protein is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found. [provided by RefSeq, Aug 2020]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).